Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 16, 2020

Osimertinib Improves Overall Survival in EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Journal of Thoracic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Osimertinib Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status
J Thorac Oncol 2020 Jul 08;[EPub Ahead of Print], J Lee, Y La Choi, J Han, S Park, HA Jung, JM Sun, SH Lee, JS Ahn, K Park, MJ Ahn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading